{'fraction_non_alphanumeric': 0.03598971722365039, 'fraction_numerical': 0.02699228791773779, 'mean_word_length': 4.992307692307692, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients

The possible onset of cardiotoxic manifestations during chemotherapy with 5-fluorouracil (5-FU) was evaluaetd in 1083 patients treated with the drug for various kinds of neoplasm. We recognized 17 cases of 5-FU cardiopathy (usually anginous crises but also myocardial infarction). The comprehensive incidence was 1.6 %, with a significantly greater risk (4.5 % vs 1.1 %) for patients with a positive anamnesis of previous cardiopathy. On the contrary, age and combination with other antiblastic drugs had no affect on the appearance of cardiopathy. We conclude that 5-FU cardiopathy, although rare, has to be taken into account in oncologic practice, chiefly in those patients already affected with cardiac diseases.